CovidVax show full list

Capsid Virus-Like Particle

AdaptVac (PREVENT-nCoV EU consortium) + University of Tubingen + Leiden University Medical Center + University of Copenhagen + ExpreS2ion Bio + Wageningen University + AGC Biologics
(Denmark + Netherlands + Germany)
vaccine type: Protein subunit
Distribution updates
currently no distribution info
Human Testing updates (clinical trials)



in definition (expecting to start Q4 2020)

Apr 24PREVENT-nCoV vaccine is expected to start clinical trials by the end of 2020 (by
Mar 09AdaptVac aims to have its vaccine complete initial clinical testing within 12 months (by
Animal Testing updates (pre-clinical trials)
Jan 12AdaptVac published in Nature Communications its preclinical studies showing strong virus neutralization for its virus like particle vaccine (by
early development updates
Nov 16PREVENT-nCoV consortium member AdaptVac announced that its vaccine has been successfully manufactured (by

2.7 million euro by EU Horizon2020
Mar 06PREVENT-nCOV EU consortium has been awarded 2,7MEUR by EU Horizon 2020 (by
May 06Bavarian Nordic has entered into agreement with AdaptVac to license its vaccine (by
Apr 24AGC selected as the manufacturer of the PREVENT-nCoV consortium vaccine (by

contact | about | ©2020 project